Drug of first choice in mild and moderate essential hypertension--clinical, hemodynamic and economic aspects.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001581:Benzothiadiazines; D003365:Costs and Cost Analysis; D004232:Diuretics; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D011224:Prazosin / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D001581:Benzothiadiazines; D004232:Diuretics; D011799:Quinazolines; D049993:Sodium Chloride Symporter Inhibitors; D011224:Prazosin